Hailed as a key growth driver for BioMarin Pharmaceuticals Inc., GALNS (N-acetylgalactosamine-6 sulfatase) came through with solid Phase III data in rare lysosomal storage disorder mucopolysaccharidosis Type IVA (MPS IVA), sending shares of the Novato, Calif.-based biotech soaring 31.2 percent Monday. Read More
With a year's worth of progress on the would-be competition targeting cholesterol by way of a new mechanism, Regeneron Pharmaceuticals Inc. and partner Sanofi SA set forth on another Phase III trial – this time measuring cardiovascular (CV) outcomes – with SAR236553/REGN727. Read More
Shares of MEI Pharma Inc. (NASDAQ:MEIP) popped on Monday morning and climbed throughout the day after the company disclosed a $27.5 million private placement. Read More
The New York Times profiled the Greek island Ikaria recently as "the island where people forget to die" for its large population (relatively speaking) of healthy individuals who are older than 80. Read More
Twenty-two UK life sciences companies and a further 10 academic groups will share £39 million (US$62.3 million) in research funding in the largest grant allocation that the Biomedical Catalyst scheme has made to date. Read More
• Can-Fite BioPharma Ltd., of Petah Tikva, Israel, said it has received a FINRA quotation clearance of its Level 1 American Depository Receipts, which will trade on the over-the-counter market under the symbol CANFY. Read More
• Genkyotex SA, of Geneva, said Phase I studies demonstrated safety and tolerability following single and multiple oral doses of GKT137831, a NOX 1 and 4 inhibitor. Read More
• The FDA's Office of Prescription Drug Promotion, Division of Professional Drug Promotion issued a letter to ONY Inc., of Amherst, N.Y., stating that materials on its website are false or misleading because they present unsubstantiated superiority claims for Infasurf, omit important risk information and make unsubstantiated claims for the product. Read More
• Ferring Pharmaceuticals SA, of Saint Prex, Switzerland, said it received confirmation from European health authorities that its marketing authorization application for its controlled release, removable misoprostol vaginal delivery system (MVDS) has been accepted for review under the decentralized procedure. Read More
• Infusions of a formulation of apolipoprotein A-I (apoA-I) – the main component of high-density lipoprotein (HDL) – rapidly increased the presence of key biomarkers associated with reverse cholesterol transport, a process by which cholesterol is removed from arteries and transported to the liver for clearance, according to data from a Phase 1 study sponsored by CSL Ltd., of Melbourne, Australia. Read More
